Biotech Values

[jb_118]

MNTA: "Craig stated unequivocally that the Top Line data alone will not be the highlight, rather, the bottom-line patient outcomes."

I didn't listen yet, so I have no context for the above summary, but to what extent is this meaning "We missed the primary endpoint (top line data), but look at how good some of these post-hoc analyses (i.e patient outcomes) are."

I don't take Craig Wheeler to be that kind of CEO, but it is par for the course for small biotech. Interested in more color on the statement (or i could just listen myself, but won't have time till monday).